PIKAMAB Awarded Two Qualifying Therapeutic Discovery Project Grants

--Intended for the Development and Commercialization of Theragnostic Products--

MENLO PARK, Calif.--(BUSINESS WIRE)-- PIKAMAB, a biopharmaceutical company specializing in stratified medicine, announced today that it has been awarded two grants by the U.S. Government under the QTDP program to advance the development and commercialization of two theragnostic products: ADCC TherasightTM and Lupus TherasightTM. PIKAMAB applied for two grants, both of which qualified and received the maximum grant amounts totaling approximately $488,959.

“We are very appreciative of the recognition and support for further development of our theragnostic products. We expect our proprietary patient stratification platforms to have transformative applications in improving the clinical trial outcomes of antibody therapies and the way we treat follicular lymphoma (B-NHL), lupus, and lupus nephritis,” commented Vijay Ramakrishnan, Ph.D., President and CEO of PIKAMAB.

The QTDP program is designed to provide grants or tax credits, as determined by the U.S. Department of Health and Human Services, to qualified biotechnology companies that demonstrate reasonable potential to (a) develop new therapies to treat cancers or chronic diseases of unmet medical needs; (b) reduce long-term health care costs in the United States; or (c) significantly advance the goal of curing cancer.

About PIKAMAB: An emerging industry leader in stratified medicine, PIKAMAB (pronounced Pick-a-MAb) is a biopharmaceutical company focused on developing efficacious therapeutic antibodies and theragnostic products to better treat cancers, autoimmune diseases, and inflammatory disorders. Through our proprietary patient stratification platforms, we can improve the clinical trial outcomes of several antibody candidates currently in clinical development, and help achieve superior therapeutic outcomes for several marketed antibody therapies. Our vision is to develop antibody therapies that are both therapeutically and economically effective in (all) patient groups. For more information, visit www.pikamab.com.


Vijay Ramakrishnan, 650-566-8344
[email protected]

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical



Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.